Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06535412
PHASE1/PHASE2

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of active SLE.

Official title: A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

218

Start Date

2024-10-10

Completion Date

2026-06-10

Last Updated

2024-08-02

Healthy Volunteers

No

Interventions

DRUG

IMC-002 + SOC

intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg

DRUG

Placebo + SOC

intravenous injection of Placebo